Clinical evaluation of cuspidoside

Abstract

In 78 patients with circulatory insufficiency, a cardiac glycoside, cuspidoside, was used as the main therapeutic agent. During therapy with cuspidoside, the initial degree of circulatory failure decreased in 72% of the surveyed. Under the influence of cuspidoside, the parameters of central hemodynamics (cardiac and stroke index, blood flow velocity, total peripheral vascular resistance) and blood flow in the liver and kidneys improved. The drug has a diuretic effect, helps to increase the content of total metabolizable potassium in the body. The research results give grounds to recommend it for wide clinical use.

Full Text

##article.viewOnOriginalSite##